Glenmark’s novel monoclonal antibody GBR 900 enters human trials
GBR 900 is a first in class monoclonal antibody for the treatment of chronic pain targeting TrkA, the receptor of NGF
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.